Gunduz Hasan Burak, Cevik Orhun Mete, Asilturk Murad, Gunes Muslum, Uysal Mustafa Levent, Sofuoglu Ozden Erhan, Emel Erhan
Department of Neurosurgery, Bakirkoy Prof. Dr. Mazhar Osman Training and Research Hospital for Neurology, Neurosurgery and Psychiatry, Istanbul, Turkey.
J Korean Neurosurg Soc. 2021 Sep;64(5):827-836. doi: 10.3340/jkns.2020.0333. Epub 2021 Jul 29.
Trigeminal neuralgia is one of the most common causes of facial pain. Our aim is to investigate the efficacy and borders of percutaneous radiofrequency thermocoagulation in the treatment of trigeminal neuralgia.
Between May 2007 and April 2017, 156 patients with trigeminal neuralgia were treated with radiofrequency thermocoagulation. These 156 patients underwent 209 procedures. In our study, we investigated the early and late results of percutaneous radiofrequency thermocoagulation under guiding fluoroscopic imaging in the treatment of trigeminal neuralgia. Barrow Neurological Institute (BNI) pain scale was used for grading the early results. In addition, Kaplan-Meier survival analysis was used to assess long-term outcomes. Of the 156 patients who underwent radiofrequency thermocoagulation for trigeminal neuralgia, 45 had additional disease. Patients with this condition were evaluated with their comorbidities. Early and late results were compared with those without comorbidity.
In 193 of 209 interventions BNI pain scale I to III results were obtained. Out of the 193 successful operation 136 patients (65.07%) were discharged as BNI I, 14 (6.70%) as BNI II, 43 (20.58%) as BNI III. Sixteen patients (7.65%) remained uncontrolled (BNI IV and V). While the treatment results of trigeminal neuralgia patients with comorbidity seem more successful in the early period, this difference was not observed in follow-up examinations.
Finally, we concluded that percutaneous radiofrequency thermocoagulation of the Gasserian ganglion is a safe and effective method in the treatment of trigeminal neuralgia. However, over time, the effectiveness of the treatment decreases. Neverthless, the reapprability of this intervention gives it a distinct advantage.
三叉神经痛是面部疼痛最常见的病因之一。我们的目的是研究经皮射频热凝术治疗三叉神经痛的疗效及范围。
2007年5月至2017年4月期间,156例三叉神经痛患者接受了射频热凝治疗。这156例患者共接受了209次治疗。在本研究中,我们调查了在X线透视引导下经皮射频热凝术治疗三叉神经痛的早期和晚期结果。采用巴罗神经学研究所(BNI)疼痛量表对早期结果进行分级。此外,采用Kaplan-Meier生存分析评估长期疗效。156例接受三叉神经痛射频热凝治疗的患者中,45例伴有其他疾病。对患有这种情况的患者及其合并症进行了评估。将早期和晚期结果与无合并症的患者进行比较。
209次治疗中有193次获得了BNI疼痛量表I至III级的结果。在这193例成功手术中,136例患者(65.07%)以BNI I级出院,14例(6.70%)以BNI II级出院,43例(20.58%)以BNI III级出院。16例患者(7.65%)疼痛未得到控制(BNI IV级和V级)。虽然合并症的三叉神经痛患者在治疗早期的结果似乎更成功,但在随访检查中未观察到这种差异。
最后,我们得出结论,半月神经节经皮射频热凝术是治疗三叉神经痛的一种安全有效的方法。然而,随着时间的推移,治疗效果会下降。尽管如此,这种干预措施的可重复性使其具有明显优势。